Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–1 of 1 matching trial from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Clear all

Withdrawn Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

NCT03851081

View directory record Official record

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions: Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Jan 27, 2022 · Synced May 21, 2026, 5:37 PM EDT